Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NuCana plc

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Compliant with All Nasdaq Continued Listing Criteria
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Announces ADS Ratio Change
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Announces Plan to Implement ADS Ratio Change
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Reports First Quarter 2025 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Prices $7 Million Registered Direct Offering
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana to Present at the Jefferies Global Healthcare Conference
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Announces Completion of ADS Ratio Change
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Announces Plan to Implement ADS Ratio Change
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana to Present at TD Cowen’s 44th Annual Health Care Conference
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana Announces Listing Transfer to Nasdaq Capital Market
From NuCana plc
Via GlobeNewswire
Tickers NCNA
NuCana to Present at the Jefferies London Healthcare Conference
From NuCana plc
Via GlobeNewswire
Tickers NCNA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.